Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIDH.L Regulatory News (IDH)

  • There is currently no data for IDH

AGM Statement

8 Sep 2011 07:00

RNS Number : 8405N
Immunodiagnostic Systems Hldgs PLC
08 September 2011
 



 

 

Immunodiagnostic Systems Holdings plc

("IDS" or "the Company")

 

AGM Statement

 

Immunodiagnostic Systems Holdings plc (AIM: IDH), a leading producer of specialist diagnostic testing kits for the clinical and research markets, will hold its Annual General Meeting today at 3.00pm at the offices of Brewin Dolphin Limited at 12 Smithfield Street, London EC1A 9BD.

 

At the meeting Chairman, David Evans, will make the following statement to shareholders:

 

"Revenues to 31 August are £22.6m compared with £18.4m for the comparative period in 2010. We have seen continued growth in our IDS-iSYS revenues which have grown £4.4m over the comparative period. As of 31 August 299 instruments have been sold or placed an increase of 58 systems since the year end and we anticipate a further 15 instruments being placed or sold in September. Average revenue per instrument is £88k compared to £72k in August 2010.

 

Our revenues are traditionally weighted to the second-half of the year and we believe this year that the trend ratio will be higher this financial year reflecting both a seasonally quieter July and August and also higher anticipated reagent / instrument sales pull-through and the anticipated continued resilience of manual product sales in the second-half.

 

The process of transition in terms of the Board has continued since the year end. We have added Roland Sackers, the CFO of QIAGEN N.V. and at the end of this meeting Anthony Martin, who has a long-established track record in the diagnostics and life sciences space, will succeed me as Chairman.

We remain active in examining the potential for licensing-out our automated IDS-iSYS platform into other disease areas not served by the Company and which can help drive value. We have ongoing discussions in autoimmune disease and in coagulation testing outside of Europe and we will keep you updated as discussions progress.

 

Finally we continue to seek acquisitions where we believe we can either add value to our existing franchise in bone and mineral disease or where we can validly exploit the IDS-iSYS asset base.

 

A more detailed trading update will be given week commencing 3rd October."

 

 

For further information:

 

Immunodiagnostic Systems Holdings plc

Tel: 0191 519 0660

Ian Cookson, Chief Executive Officer

Paul Hailes, Finance Director

 

 

 

Brewin Dolphin

Tel: 0845 213 4930

Matt Davis

Sean Wyndham-Quin

 

 

 

Walbrook PR Ltd

Tel: 020 7933 8780

Paul McManus

paul.mcmanus@walbrookpr.com

Fiona Henson

fiona.henson@walbrookpr.com

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGMSSAFWWFFSEFU
Date   Source Headline
10th Sep 20147:00 amRNSAcquisition of Dia.Metra S.r.l.
21st Aug 20147:00 amRNSChinese FDA clearance for the IDS-iSYS instrument
4th Aug 20145:59 pmRNSAGM Results
4th Aug 20147:00 amRNSAGM Statement
30th Jul 201410:25 amRNSAdditional Listing
14th Jul 201411:36 amRNS2014 Annual Report & Accounts and Notice of AGM
24th Jun 20147:00 amRNSFinal Results
12th May 201410:51 amRNSHolding(s) in Company
15th Apr 20147:00 amRNSTrading Statement
13th Mar 20144:40 pmRNSSecond Price Monitoring Extn
13th Mar 20144:35 pmRNSPrice Monitoring Extension
7th Mar 20147:00 amRNSDirectorate Change
15th Jan 20144:28 pmRNSHolding(s) in Company
9th Jan 20147:00 amRNSFDA clearance of Direct Renin assay on IDS-iSYS
8th Jan 201412:47 pmRNSAdditional Listing
19th Dec 20134:36 pmRNSAdditional Listing
12th Dec 20136:20 pmRNSHolding(s) in Company
12th Dec 20136:19 pmRNSHolding(s) in Company
27th Nov 20137:00 amRNSHalf Yearly Report
10th Oct 20137:00 amRNSTrading Statement
8th Oct 20134:29 pmRNSHolding(s) in Company
8th Oct 20134:26 pmRNSHolding(s) in Company
27th Sep 201312:40 pmRNSHolding(s) in Company
24th Sep 20131:15 pmRNSAdditional Listing
4th Sep 20137:00 amRNSHolding(s) in Company
28th Aug 201312:46 pmRNSAdditional Listing
31st Jul 201312:20 pmRNSAdditional Listing
29th Jul 20133:24 pmRNSHolding(s) in Company
26th Jul 20133:08 pmRNSResult of AGM
26th Jul 201312:00 pmRNSAGM Statement
2nd Jul 20139:41 amRNSDirector/PDMR Shareholding
28th Jun 20139:46 amRNSAdditional Listing
28th Jun 20139:00 amRNSAnnual Report and AGM
26th Jun 20137:00 amRNSAdditional Listing
24th Jun 20137:00 amRNSFDA clearance of 1,25-Dihydroxy Vitamin D assay
21st Jun 20137:00 amRNSImmunodiagnostic Systems streamlines Board
17th Jun 20137:00 amRNSFinal Results
10th May 20134:29 pmRNSHolding(s) in Company
9th May 20133:22 pmRNSAdditional Listing
2nd May 20137:41 amRNSEntry into Chinese Diagnostics Market
25th Apr 20134:17 pmRNSTrading Update - Replacement
23rd Apr 20139:45 amRNSHolding(s) in Company
16th Apr 20135:03 pmRNSHolding(s) in Company
16th Apr 201311:42 amRNSHolding(s) in Company
10th Apr 20137:00 amRNSDistribution Agreement
10th Apr 20137:00 amRNSTrading Statement
5th Apr 201310:22 amRNSDirector/PDMR Shareholding
4th Apr 20134:43 pmRNSHolding(s) in Company
11th Feb 20137:00 amRNSCollaboration with Diagnostica Stago
14th Dec 20122:28 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.